Spero Therapeutics (SPRO) Invested Capital (2016 - 2026)

Spero Therapeutics (SPRO) has reported Invested Capital for 11 consecutive years, with $44.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital changed N/A year-over-year to $44.3 million; the trailing twelve-month figure through Jun 2026 stood at $44.3 million (changed N/A YoY), and the FY2025 full-year result was $59.1 million, up 28.16% from the prior year.
• Invested Capital eased to $44.3 million in Q2 2026 per SPRO's latest filing, from $53.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $107.0 million in Q4 2023 and bottomed at $32.7 million in Q3 2022.
• Historically, Invested Capital has averaged $62.3 million across 5 years, with a median of $59.1 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Invested Capital plunged 70.79% in 2022, then soared 64.26% in 2023.
• Over 5 years, Invested Capital stood at $76.0 million in 2022, then soared by 40.71% to $107.0 million in 2023, then plunged by 56.89% to $46.1 million in 2024, then advanced by 28.16% to $59.1 million in 2025, then decreased by 25.07% to $44.3 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $44.3 million, $53.0 million, and $59.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.